MARK2 and breast cancer: mTOR is an atypical serine-threonine kinase, present between mTORC1 and raptor and PRAS40, and between mTORC2 and rictor, mSIN1 and protor-1/2 (38), is one of the most frequently activated pathways in BC (39).